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Introduction
Progressive muscular atrophy (PMA) was first described in 1848 by 
F. A. Aran, who reported 11 cases of weakness and paresis of the 
upper limbs (Bonduelle, 1989). However, it was not until 1869 that 
French neurologist Jean-Martin Charcot classified amyotrophic lat-
eral sclerosis (ALS) as a separate neurodegenerative motor neuron 
disorder (MND) from PMA. It was not until 1874 that ALS was given 
the name of amyotrophic lateral sclerosis in Dr. Charcot’s “Oeuvres 
Completes.” In his earliest studies, he noted that, “lesions within the 
lateral column in the spinal cord resulted in chronic progressive pa-
ralysis and contractures (no atrophy of muscles), while lesions of 
the anterior horn of the spinal cord resulted in paralysis without 
contractures (with atrophy of muscles)” (Goetz, 2000). ALS shares 
many clinical symptoms to other MNDs such as: spinal muscular 
atrophy, primary lateral sclerosis and bulbar palsy. The key to ALS’s 
understanding was due to Dr. Charcot’s unique method known as 
“anatomo-clinical method.” Using this technique he was able to de-
termine the correlation between clinical signs detected during life 
and anatomical lesions seen at death. Furthermore, post-mortem 
studies revealed both the anterior horn cell lesion typical of acute 
amyotrophy, and also the distinctive bilateral and symmetric sclerosis 
of the lateral spinal cord columns. Hence, he named the syndrome 
ALS, since it incorporated the two aspects of gray matter involve-
ment (amyotrophy) and white matter damage (lateral sclerosis). Dr. 
William Gowers, though, argued with Charcot’s terminology since 
it suggested that lateral sclerosis was primary and amyotrophy was 
secondary, and instead, postulated they are one event (Goetz, 2000). 
This is still debated over a century later.
ALS is an incurable disease that has an incidence of approximately 
2 in every 100,000 people. The mean age of onset for ALS is 55-60 
and affects men more than women. No diagnostic test exists for 
ALS. Physicians only diagnose ALS when both upper and lower 
motor neurons are affected and after ruling out all other causes 
. At first, one may notice weakness in an arm or leg, described as 
“limb onset” of ALS, or difficulty with speech production, known 
as “bulbar onset” ALS, which quickly spread to other parts of the 
body. Eventually, all limbs and movement cease, leading to com-
plete paralysis. Since ALS shares several common symptoms with 
spinal muscular atrophy and other neurological conditions, sev-
eral tests are required to diagnose. Presently, the only tests, aside 
from limited genetic testing, vary from electromyography (EMG) 
and nerve conduction study (NCS) to magnetic resonance imag-
ing (MRI). After all these tests are performed, physicians still may 
not know until later stages of the disease. 
Presently, the cause of ALS is unknown. Some research points 
out that ALS results from inaccurate protein formation. Other 
research demonstrates there is an excess of glutamate in the syn-
apses causing neurite toxicity. Still other research shows chang-
es to RNA processing. A fourth theory suggests environmental 
factors since U.S. military personnel in the Gulf War had higher 
incidence of developing ALS (Haley 2003).
Genetic mutations in ALS are numerous, for instance, superox-
ide dismutase 1 (SOD1), chromosome 9 open reading frame 72 
(C9orf72), TAR DNA-binding protein 43 (TDP-43), senataxin 
(SETX) and fused in sarcoma (FUS) are a few of the growing list 
of genetic mutations associated with ALS. In contrast, spinal mus-
cular atrophy (SMA) has only one genetic mutation in survival 
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motor neuron 1/2 (SMN1/2). SMA shares some common fea-
tures with ALS, such as lower motor neuron degeneration, gem 
depletion and possibly biomarkers.
ALS and SMA share a biochemical pathway in gem depletion re-
lated to each disease’s respective genetic mutation (TDP-43 and 
SMN) (Yamazaki, 2012; Groen et al., 2013; Turner, 2014, Rafałowska 
et al., 2014). Also, both selectively target motor neurons although 
SMN1, SMN2, TDP-43, SETX and FUS are ubiquitously expressed 
(Cauchi, 2014; Achsel et al., 2013; Tsuiji et al., 2013).  A project 
called: Biomarker identification for SMA (BforSMA) has yielded 
significant results for future clinical studies (Finkel et al., 2012). 
ALS biomarker identification would also accelerate future clinical 
trials. SMA has had much more success in diagnosis and progno-
sis than ALS due to its monogenic nature, while many of ALS’s 
genetic mutations are still being discovered (Keller et al., 2014). 
Nonetheless, there appears to be a strong relationship between 
these two disparate MNDs. By researching the overlap of these 
two MNDs a common therapeutic approach may be possible. 
As of yet, it remains unknown why ALS and SMA, which have 
genes that are ubiquitously expressed, selectively destroy motor 
neurons.
Methods
Peer-reviewed articles from PubMed and UptoDate (a division of 
Wolters Kluwer Health) using keywords “Amyotrophic Lateral 
Sclerosis” “ALS” “Genetic basis of ALS” “Biomarkers for ALS” 
“Spinal Muscular Atrophy” “SMA” “SMA and ALS” were utilized 
as background for this paper. Dr. Alex Pearlman and Dr. Harry 
Ostrer also provided guidance in developing this thesis.
Theories on Targeted Motor Neuron 
Degeneration in ALS
ALS is a heterogeneous disease with multiple pathogenic mech-
anisms and variable sites of disease onset and progression. 
Researchers currently are searching for the starting point of the 
disease and the reason why motor neurons are specifically tar-
geted. Present research focuses on aberrant protein formation in 
axons, excess glutamate activity in neuromuscular synapses and 
gem depletion in cells as being responsible for ALS pathology. 
The first hypothesis on ALS pathogenesis is faulty protein for-
mation in axons. According to Dr. Zhang, at the University of 
Madison-Wisconsin, misfolded protein in neurons causes a 
cascade of events (Chen et al., 2014). Eventually, the protein is 
shuttled to the distal part of the axon, but becomes tangled in 
transport and axonal degeneration occurs. This may also explain 
Alzheimer’s and Parkinson’s disease and their pathophysiology. 
Through use of induced pluripotent stem cells (iPSCs), Dr. Zhang 
formed new nerve cells in vitro and tested his hypothesis (Chen 
et al., 2014). Indeed, when patient iPSCs were used, neurofilament 
(NF) aggregation together with neurite swelling in spinal motor 
neurons (MN) resulted. “Such MN-selective NF changes were 
mimicked by expression of a single copy of mutant SOD1 (D90A) 
in human embryonic stem cells (hESCs) and prevented by genetic 
correction of the SOD1 mutation in patient iPSCs” (Chen et al., 
2014). “A4V is the most common SOD1 mutation in the US and 
D90A is most common in Europe” (Giannini et al., 2010; Saeed 
et al., 2009). In ALS MNs bead like structures form along neurites. 
These bead like structures have heavy immunostaining for plasma 
phosphorylated neurafilament-H. Plasma phosphorylated neura-
filament-H levels closely reflect disease progression in SOD1 
(G93A) mice and are regarded as an ALS biomarker (Calvo et 
al., 2012). Therefore, the bead like structures that were heavily 
phosphorylated with plasma phosphorylated neurafilament-H, 
indicated pathogenicity. As opposed to control MNs and non-
MNs that have an even staining pattern. This finding highlights the 
possibility of targeting NF regulation for therapeutic intervention.
A second hypothesis on the pathogenesis of ALS is excess 
glutamate accumulation, which causes neuro-degeneration. 
“Glutamate is generally acknowledged to be the most import-
ant transmitter for normal brain function” (Purves et al., 2001). 
Glutamate is an excitatory neurotransmitter. However, high 
extracellular glutamate can have toxic effects on neurons. It is 
synthesized in neurons from precursors. In a Human Molecular 
Genetics paper by Dr. Guo he explains that glial glutamate trans-
porter, excitatory amino acid transporter (EAAT2 also known as 
GLT1), is responsible for removing glutamate from the synaptic 
cleft (Guo et al., 2003). In ALS patients, the glutamate transporter 
EAAT2 has been found inactive. Defective glutamate transport 
and loss of EAAT2 protein have also been observed in affect-
ed brain regions of patients with Alzheimer’s disease (Masliah 
et al., 1996). Overactivation of glutamatergic neurons can result 
in a neurodegenerative process known as excitotoxicity i.e. cell 
death. (Guo et al., 2003). “However, it is still unknown whether 
it is a primary cause in the cascade leading to neuron degenera-
tion or a secondary event to cell death” (Guo et al., 2003). After 
experimentation with transgenic mice, containing increased ex-
pression of EAAT2 and SOD1 variation (G93A) degeneration of 
neurons was slowed, but did not cease. The results “suggest that 
the loss of EAAT2 may contribute to, but does not cause, motor 
neuron degeneration in ALS” (Guo et al., 2003). Transgenic mice 
with the common mutations of SOD1 exhibit neurodegenera-
tion comparable to ALS. The SOD1 mutation results in a toxic 
gain of function rather than a loss of enzymatic function (Wong 
et al., 1995). Furthermore, in a Nature paper by Dr. Rothstein 
he demonstrates β-lactam antibiotics, for example, ceftriaxone, 
a semi-synthetic, third generation cephalosporin antibiotic, has 
been used to treat bacterial infections (Rothstein et al., 2005). 
These antibiotics also show no substantial toxic CNS effects. 
Additionally, they have found it to increase gene expression 
85
ALS and Spinal Muscular Atrophy: A Genetic Linkage? 
of GLT1. Leading to neuroprotection by increasing glutamate 
transporter expression. The mechanism of this overexpression 
appears to be activation of the genetic promoter for GLT1, al-
though the pathway for promoter activation is, as yet, unknown. 
(Rothstein et al., 2005). This too provides another possible inter-
vention of ALS, which is currently in phase 3 clinical trials (Berry 
et al., 2013). Note that the only drug currently available for ALS 
is Riluzole. It provides no relief of symptoms, but slows the prog-
ress of the syndrome by decreasing glutamate accumulation.
ALS and SMA Overlap
A third hypothesis for ALS disease onset is gem depletion. Gems 
or gemini of Cajal bodies are protein products of SMN, TDP-43, 
FUS and SETX located in nuclear foci and in the cell cytoplasm 
responsible for the assembly of small nuclear ribonucleoproteins 
(snRNPs) (Tsuiji et al., 2013; Achsel et al., 2013; Cauchi, 2014). In 
spinal motor neurons with TDP-43 mutations there are depleted 
gems, snRNPs and small nuclear ribonucleotides (snRNAs) (Tsuiji 
et al., 2013). TDP-43 and FUS localize within nuclear gems togeth-
er with the SMN complex and are involved in the maintenance 
of the spliceosome by controlling levels of snRNA (Tsuiji et al., 
2013). It was further shown that accumulation of spliceosomes 
cause aberrant splicing of mRNAs resulting in motor neuron 
death in ALS and SMA. To clarify what gems are, how they relate 
to SMN, TDP-43 and FUS and the link between spliceosomes and 
motor function, Dr. Ruben Cauchi explains succinctly the RNA 
processing pathway. The pathway starts with the SMN-Gemins 
complex consisting of a nine-membered union of diverse pro-
teins. More specifically, these are SMN, seven Gemin proteins 
(Gemin2-Gemin8) (Carissimi et al., 2006) and Unrip (Carissimi 
et al., 2005). The SMN-Gemins complex establishes the snRNP 
assemblyosome. “SnRNPs are composed of one or two short 
noncoding RNA molecules (snRNAs) bound to a set of seven 
Smith (SM or Sm-like (Lsm) proteins, and a unique set of sn-
RNP-specific proteins” (Matera, Terns, & Terns, 2007). 
Working together with numerous non-snRNP splicing factors, 
U1, U2, U4/U6 and U5 snRNPs form the more abundant spli-
ceosome that is responsible for splicing introns from pre-mRNA; 
as opposed to, U11, U12 U4atac/U6atac and U5 snRNPs that 
constitute the less available spliceosome (Patel & Steitz, 2003). 
The Lsm-class U6 and U6atac snRNPs, though, are synthesized 
in the nucleus while the core structure of the remaining Sm-
class snRNPs is assembled in the cytoplasm. The published work 
on these interactions is fairly recent, and it is still is not fully 
understood why in vivo requires the action of the SMN-Gemins 
complex (Otter et al., 2007) and involves the uploading of a hep-
tameric Sm D1/D2/E/F/G/D3/B ring-shaped core domain onto 
the “Sm site,” a conserved uridine-rich sequence motif intrinsic 
to snRNAs (Cauchi, 2014).
The snRNAs expelled from the nucleus following transcription 
are tagged by SMN-Gemins complex-independent Gemin5 pro-
tein. Once Gemin5 is charged with snRNAs it binds with SMN-
Gemin complex, proximate to Gemin2, to form the Sm core 
assembly. Gemin2 is essential for the majority of Sm proteins rec-
ognition to form the ring-shaped domain. It also blocks foreign 
RNA binding supposedly until bona fide RNA substrates, snRNAs, 
are identified. (Zhang et al., 2011) (Figure 1). SMN’s function in 
snRNP assembly, according to many, is the most decisive of all the 
SMN-Gemins complex members (Cauchi, 2014) and is probably 
linked to axonal mRNP trafficking (Fallini, Bassell, & Rossoll, 2012; 
Briese, Esmaeili, & Sattelle, 2005). Proper Sm core assembly is 
necessary not only for stability and function of snRNPs, but also 
for snRNP biogenesis, including cap hypermethylation, 3` terminal 
trimming and eventual import into the nucleus. Once in the nu-
cleus, snRNPs mature in Cajal Bodies (CBs) prior to pre-mRNA 
splicing. After multiple splicing procedures, snRNPs return to the 
CBs where they are regenerated or recycled (Staněk et al., 2008).
Mutations in the copy numbers of SMN1 and the identical gene of 
SMN2 are the principal etiologic basis of SMA cases. The number 
of copy numbers in SMN2 is inversely correlated with disease 
severity. One of the main theories explaining SMA is improper 
mRNA processing. According to the above, the fewer normal 
SMN proteins cause a lack of SMN-Gemins complex essential 
for pre-mRNA splicing (Borg & Cauchi, 2013; Briese et al., 2009). 
Phenotypic SMA effects have been modeled in fly, zebrafish and 
mouse models with insufficient levels of SNM protein (Burghes 
& Beattie, 2009; Briese et al., 2009). Gemins mutations, however, 
have not been associated with SMA. Investigators hypothesize 
SMN is unique in human genetics and a SMN2-like pseudogene in 
any of the Gemins would be incompatible with life. Dr. Cauci con-
ducted an experiment with organisms containing reduced levels 
of Gemins selectively in motor neurons. Organisms with this 
defect develop similar motor deficits found in the attenuation of 
SMN. Therefore, inadequate levels of any member in the SMN-
Gemins complex can cause motor deficits. Decreased capacity 
of the SMN-Gemins complex can account for neuromuscular 
selectivity, based on sequencing of RNA from microdissected 
motor neurons of presymptomatic SMA mice; there are specific 
transcriptome abnormalities that link SMN deficiency to motor 
neuron pathology in SMA (Zhang et al., 2013).
The function of Gems is thought to colocalize with CBs in later 
developmental stages. Gems are viewed as storage depots for 
supplementary SMN-Gemins complexes since upregulation of 
SMN or Gemins induces gem formation or increases gem num-
bers (Cauchi 2011, Turner et al., 2014). Additionally, when there 




ALS and SMA phenotypes affect lower motor neurons in the 
anterior horn of the spinal tract. There is a common tract and 
biochemical pathway that both MNDs share. ALS can also affect 
the upper motor neurons. Two of the more common genetic mu-
tations found in ALS are TDP-43 and FUS. (Millecamps et al., 2010; 
Tsai et al., 2011). Surprisingly, these two genes engage in RNA 
processing. Under pathogenic conditions, the proteins of each 
are found concentrated in the cytoplasm and not in the nucleus 
in both neuronal and glial cells. This suggests there is a loss of 
proper nuclear function or toxic gain of function pertinent to 
ALS pathogenesis (Andersen & Al-Chalabi, 2011; Ferraiuolo et al., 
2011; Lagier-Tourenne, Polymenidou, & Cleveland, 2010).
SMN has been found in decreased levels in transgenic SOD1 mu-
rine models (Turner, 2009) and SMN protein levels were reduced 
in ALS patients (Turner, 2014). This agrees with previous evidence 
relating decreased copy numbers of SMN2 to increased severity 
of ALS. (Veldink, 2005). Furthermore, loss of the SMN2 protein 
caused gem depletion in motor neurons, and knockout mice of 
TDP-43 showed altered numbers of gems (Shan et al., 2010). In 
ALS patient derived cells with TDP-43 or FUS mutations, the gem 
numbers are significantly reduced too (Yamazaki et al., 2012). 
Also, biochemical experiments have shown that TDP-43 and FUS 
interact with the SMN-Gemins complex (Yamazaki et al., 2012, 
Tsuiji et al., 2013). 
Biomarker Identification
Since both ALS and SMA are swift and crippling diseases, early 
diagnosis is essential for prognosis and future treatment options. 
Although, genetic testing is a current diagnostic tool for SMA, 
it does not test for all mutations in SMA, and is a premium that 
most cannot afford. Additionally, it does not provide a test for 
treatment response. Previous clinical trials for both ALS and SMA 
have produced no complete treatments for humans. There is a 
need to develop biomarkers that can help deliver quicker results 
from research into practice. At the same time, biomarkers facili-
tate the discovery of novel targets and pathways in pathogenesis.
One of the most successful approaches for diagnosis is biomark-
er identification, incorporating: proteomics, metabolomics and 
transriptomics. Biomarker identification is not new to transla-
tional medicine. Biomarkers have been used tremendously in 
the cancer field and they are beginning to show promise in SMA 
too. After a recent cross-sectional study in Biomarkers for SMA 
(BforSMA), the top 5 biomarker candidates: CILP2, TNXB, COMP, 
ADAMTSL4 and CLEC3B may be used for diagnosis and testing 
response to treatment after further testing (Finkel (2012). A lon-
gitudinal study will be necessary to qualify the results of BforSMA. 
The BforSMA isolated the candidate plasma proteins, metabolites 
based on type of SMA presented since type I will produce pos-
sible differences than type II or III. Transcripts, though, did not 
provide significant candidates in the BforSMA. The potential from 
the BforSMA is tremendous for future clinical trials and reduc-
tion in patients and costs associated with studies. ALS would also 
benefit from biomarker identification.
All of the BforSMA are only from peripheral blood mononuclear 
cells. As a result, there was an absence of change in gene ex-
pression or splicing suggesting that the degree of reduction of 
the SMN protein in this tissue is not enough to cause dramatic 
changes. This would be consistent with the fact that blood and 
other tissues do not exhibit the change of cellular or organ func-
tion except in Type I SMA. Since SMN protein is known to have 
reduction concurrent with genetic mutations in ALS, some of the 
biomarkers not tested for in BforSMA may serve as an interest-
ing study for a common biomarker between these two seemingly 
disparate diseases.
Following the BforSMA study, a publication by Dr. Robert Bowser 
outlines biomarkers that have been discovered recently in trans-
genic models that may best represent ALS patients, along with 
prognostic determinants for ALS. Some of the biomarkers high-
lighted are SOD1 in the cerebrospinal fluid (CSF), increased 
levels of NF in blood/CSF, increased expression of CD4+ T 
cells (Bakkar, Boehringer, & Bowser, 2014). Some of the positive 
prognostic markers for ALS are low pNF-H, high sCD14 and low 
S100B in blood/CSF (Bakkar, Boehringer, & Bowser, 2014). A dis-
advantage of these biomarkers is that they are only tested from 
transgenic models unlike the BforSMA, which tested human SMA 
patients. As with the BforSMA, longitudinal studies are necessary 
to qualify these findings. 
There is significant evidence of genetic and mechanistic inter-
action between SMA and ALS. Unfortunately the low rate inci-
dence of ALS – approximately 2 in every 100,000 people – has 
limited the expenditure of resources into the understanding of 
the pathogenesis and treatment of this disease.   Thus any link-
age between ALS and the more common disorder of SMA may 
prove extremely beneficial.   With further research on the shared 
pathways and possible common biomarkers of ALS and SMA, 
therapies of MNDs may emerge that may combat the devastating 
consequences of both of these neurodegenerative disorders.  
Future Directions
To further clarify the potential linkage, between SMA and ALS, 
both the limb- and bulbar- onset types of ALS must be brought 
under a more uniform classification scheme that recognizes the 
homogeneity of these diseases which may then be applied to 
SMA. The elucidation of the genetic make-up of ALS may also lead 
to a common gene for multiple sites of origin.  Moreover, some 
genetic mutations in ALS may also be shown to augment symp-
toms common in SMA. The fact that both of these MNDs affect 
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lower motor neuron function and share a common biochemical 
pathway in pathogenesis may lead to other insights into the in-
teraction between these MNDs.   Biomarker identification will 
likely prove extremely useful in future clinical trials as a potential 
possible diagnostic tool.
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